Comparative Pharmacology
Head-to-head clinical analysis: ARAVA versus HYDROXYCHLOROQUINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAVA versus HYDROXYCHLOROQUINE SULFATE.
ARAVA vs HYDROXYCHLOROQUINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leflunomide inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, thereby reducing T cell proliferation.
Antimalarial and immunosuppressive agent. Accumulates in lysosomes, raising pH, impairing antigen processing and presentation. Inhibits toll-like receptor signaling and cytokine production (e.g., IL-6, TNF-α). Interferes with quinone reductase activity and heme polymerization in plasmodia.
100 mg orally once daily for 3 days (loading dose), then 20 mg orally once daily (maintenance); if not tolerated, may reduce to 10 mg orally once daily.
200-400 mg orally once daily or divided twice daily; maximum 600 mg/day or 6.5 mg/kg/day (whichever is lower). For malaria: 800 mg loading dose, then 400 mg at 6, 24, and 48 hours.
None Documented
None Documented
The terminal elimination half-life of teriflunomide is approximately 18–19 days due to enterohepatic recirculation. This long half-life necessitates a loading dose and may prolong time to steady state (>3 months).
Terminal half-life: ~40–50 days (range 30–60 days) due to extensive tissue distribution. Steady-state reached after 4–6 months.
Following oral administration, ~90% of a dose is excreted in feces (primarily as parent drug and M1 metabolite) and ~10% in urine (M1 metabolite). Biliary excretion is a major route for the active metabolite teriflunomide.
Renal: ~50% unchanged; Hepatic metabolism: ~50% (desethylchloroquine, desethylhydroxychloroquine); Fecal: minimal (<5%).
Category C
Category A/B
DMARD
Antimalarial / DMARD